Olema Pharmaceuticals insider gifts 35,868 shares after option exercise

Rhea-AI Filing Summary

Olema Pharmaceuticals, Inc. director reported an option exercise and a subsequent charitable gift of common stock. On 11/21/2025, the reporting person exercised a stock option and acquired 35,868 shares of Olema common stock at an exercise price of $0.39 per share. After this exercise, the same number of shares was held directly.

On 11/25/2025, the reporting person transferred 35,868 shares as a bona fide gift for no consideration to the Rappaport Family Foundation, a charitable foundation where the reporting person serves as an officer and has voting and dispositive power over the securities it owns. Following the reported transactions, the reporting person no longer holds Olema shares directly but reports 385,965 shares held indirectly through the Rappaport Family Trust, of which the reporting person is co‑trustee.

Insider Trade Summary

35,868 shares exercised/converted

Mixed 4 txns

Insider RAPPAPORT ANDREW

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	35,868	$0.00	--
Exercise	Stock Option (right to buy)	35,868	$0.00	--
Exercise	Common Stock	35,868	$0.39	$14K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 0 shares (Direct); Stock Option (right to buy) — 0 shares (Direct); Common Stock — 385,965 shares (Indirect, See Footnote)

Footnotes (1)

1. The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation. The shares are held by the Rappaport Family Trust, of which the reporting person is co-trustee. The shares subject to the option are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAPPAPORT ANDREW

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		M		35,868	A	$0.39	35,868	D
Common Stock	11/25/2025		G(1)		35,868	D	$0	0	D
Common Stock								385,965	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.39	11/21/2025		M			35,868	(3)	12/20/2025	Common Stock	35,868	$0	0	D

Explanation of Responses:

1. The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation.

2. The shares are held by the Rappaport Family Trust, of which the reporting person is co-trustee.

3. The shares subject to the option are fully vested.

	/s/ Shane Kovacs, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Olema Pharmaceuticals (OLMA) report on this Form 4?

The filing reports that a director of Olema Pharmaceuticals, Inc. (OLMA) exercised a stock option for 35,868 shares of common stock at $0.39 per share on 11/21/2025, then transferred those 35,868 shares as a bona fide charitable gift on 11/25/2025.

How many Olema (OLMA) shares did the insider acquire and at what price?

The insider acquired 35,868 shares of Olema common stock through the exercise of a stock option with an exercise price of $0.39 per share on 11/21/2025.

What was the nature of the share transfer reported by the Olema (OLMA) director?

The filing states the reporting person transferred 35,868 shares to the Rappaport Family Foundation as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation.

How many Olema (OLMA) shares does the insider report owning after these transactions?

After the reported transactions, the insider reports owning 0 shares directly and 385,965 shares indirectly through the Rappaport Family Trust, of which the reporting person is co‑trustee.

What happened to the stock option reported in the Olema (OLMA) Form 4?

The Form 4 shows a stock option with an exercise price of $0.39 covering 35,868 shares of Olema common stock. The option was exercised on 11/21/2025, and the filing notes that the shares subject to the option were fully vested.

What is the reporting person’s relationship to Olema Pharmaceuticals (OLMA)?

The reporting person is identified as a director of Olema Pharmaceuticals, Inc. and files the Form 4 as a single reporting person.